Get the Stockscreener App
0.3276
1.36%
0.0044
After Hours:
.33
0.0024
+0.73%
Turnstone Biologics Corp stock is traded at $0.3276, with a volume of 47,062.
It is up +1.36% in the last 24 hours and down -10.25% over the past month.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
See More
Previous Close:
$0.3232
Open:
$0.3206
24h Volume:
47,062
Relative Volume:
0.46
Market Cap:
$7.58M
Revenue:
$81.89M
Net Income/Loss:
$-55.20M
P/E Ratio:
-0.1215
EPS:
-2.6959
Net Cash Flow:
$-67.40M
1W Performance:
-1.59%
1M Performance:
-10.25%
6M Performance:
-36.85%
1Y Performance:
-87.54%
1-Day Range:
$0.3128
$0.3339
1-Week Range:
$0.3128
$0.3499
52-Week Range:
$0.29
$3.05
Turnstone Biologics Corp Stock (TSBX) Company Profile
Name
Turnstone Biologics Corp
Sector
Industry
Phone
347-897-5988
Address
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Compare TSBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.3276 | 7.85M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-14-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-16-23 | Initiated | SVB Securities | Market Perform |
| Aug-15-23 | Initiated | BofA Securities | Buy |
| Aug-15-23 | Initiated | Piper Sandler | Overweight |
View All
Turnstone Biologics Corp Stock (TSBX) Latest News
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Turnstone Biologics Reports Q1 Loss Amid Strategic Shift - TipRanks
Turnstone Biologics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights - The Manila Times
Turnstone Biologics Reports Q1 2025 Financial Results and Updates on Strategic Alternatives - Nasdaq
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent - Bluefield Daily Telegraph
Turnstone Biologics (NASDAQ:TSBX) Shares Up 0.8% – Still a Buy? - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.29 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.29 - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.33 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.33 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.34 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.34 - Investing.com
Q1 EPS Forecast for Turnstone Biologics Decreased by Analyst - Defense World
Analysts Set Expectations for TSBX Q1 Earnings - Defense World
Turnstone Biologics Corp: Strategic Partnerships and Financial Position Justify Hold Rating - TipRanks
Turnstone Biologics Reports 2024 Financial Results - TipRanks
Turnstone Biologics moves to Nasdaq Capital Market By Investing.com - Investing.com South Africa
Turnstone Biologics moves to Nasdaq Capital Market - Investing.com
Turnstone Biologics Corp. SEC 10-K Report - TradingView
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Turnstone Biologics Cuts Losses by $3.6M as Company Pivots Strategy - Stock Titan
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Growth in Short Interest - Defense World
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World
Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com Australia
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
Turnstone Biologics Corp Stock (TSBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):